Advertisement

Breast Cancer Research and Treatment

, Volume 155, Issue 2, pp 365–373 | Cite as

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study

  • Joanne Kotsopoulos
  • Tomasz Huzarski
  • Jacek Gronwald
  • Pal Moller
  • Henry T. Lynch
  • Susan L. Neuhausen
  • Leigha Senter
  • Rochelle Demsky
  • William D. Foulkes
  • Charis Eng
  • Beth Karlan
  • Nadine Tung
  • Christian F. Singer
  • Ping Sun
  • Jan Lubinski
  • Steven A. NarodEmail author
Epidemiology

Abstract

Many BRCA1 mutation carriers undergo elective surgical oophorectomy (often before menopause) to manage their elevated risk of developing ovarian cancer. It is important to clarify whether or not the use of hormone replacement therapy (HRT) to mitigate the symptoms associated with surgical or natural menopause is safe in women with an inherited BRCA1 mutation and no personal history of breast or ovarian cancer. We conducted a case–control analysis of 432 matched pairs of women with a BRCA1 mutation. Detailed information on HRT use after menopause (duration, type, age at first/last use, formulation) was obtained from a research questionnaire administered at the time of study enrollment. Conditional logistic regression was used to estimate the odds ratio (OR) and 95 % confidence intervals (CI) associated with HRT use. The mean duration of HRT use after menopause was 4.3 years among the cases and 4.4 years among the controls (P = 0.83). The adjusted OR for breast cancer comparing all women who ever used HRT to those who never used HRT was 0.80 (95 % CI 0.55–1.16; P = 0.24). Findings did not differ by type of menopause (natural vs. surgical), by recency of use, by duration of use, and by formulation type. These findings suggest that a short course of HRT should not be contra-indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer.

Keywords

BRCA1 Hormone replacement therapy Breast cancer 

Notes

Acknowledgments

We would also like to thank the study coordinators Marcia Llacuachaqui, Farah Shoukat, and Alejandra Ragone, as well as the students and staff Ellen MacDougall, Zoella Pasta, Nida Mian, Jennifer Ng, Sarah Chin, Hamida Begum, Harmeet Chaudhary, and Yaminee Charavanapavan who helped with the data collection and data entry. Joanne Kotsopoulos is the recipient of a Cancer Care Ontario Research Chair in Population Studies and a Canadian Cancer Society Career Development Award in Prevention. Charis Eng is the recipient of the Sondra J. and Stephen R. Hardis Chair of Cancer Genomic Medicine at the Cleveland Clinic and of the ACS Clinical Research Professorship. Susan L. Neuhausen was partially supported by the Morris and Horowitz Endowed Professorship, and her work was supported by a grant from the National Cancer Institute, National Institutes of Health (R01CA74415). Steven A. Narod is the recipient of a Tier I Canada Research Chair. This study was supported by a Canadian Cancer Society Research Institute grant (703058). Patients were recruited for study from the City of Hope Clinical Cancer Genomics Community Research Network, supported in part by Award Number RC4CA153828 (PI: J. Weitzel) from the National Cancer Institute and the Office of the Director, National Institutes of Health. Siranoush Manoukian is affiliated with the Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.

Compliance with ethical standard

Competing Interests

The authors declare that they have no conflict of interest.

References

  1. 1.
    Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047–1059CrossRefGoogle Scholar
  2. 2.
    Rossouw JE et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMedGoogle Scholar
  3. 3.
    Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427CrossRefPubMedGoogle Scholar
  4. 4.
    Chen WY et al (2004) Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 101(7):1490–1500CrossRefPubMedGoogle Scholar
  5. 5.
    Beral V et al (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103(4):296–305PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Narod SA (2011) Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 8(11):669–676CrossRefPubMedGoogle Scholar
  7. 7.
    Chlebowski RT et al (2013) Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. J Natl Cancer Inst 105(8):26–35CrossRefGoogle Scholar
  8. 8.
    Anderson GL et al (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 13(5):476–486PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Reeves GK et al (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918CrossRefPubMedGoogle Scholar
  10. 10.
    Kotsopoulos J et al (2010) Risk factors for ductal and lobular breast cancer: results from the nurses’ health study. Breast Cancer Res 12(6):R106PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Clarke CA et al (2006) Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24(33):e49–e50CrossRefPubMedGoogle Scholar
  12. 12.
    Eheman CR et al (2009) The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004. Cancer Epidemiol Biomarkers Prev 18(6):1763–1769CrossRefPubMedGoogle Scholar
  13. 13.
    Kumle M (2008) Declining breast cancer incidence and decreased HRT use. Lancet 372(9639):608–610CrossRefPubMedGoogle Scholar
  14. 14.
    Eisen A et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100(19):1361–1367PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Rebbeck TR et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23(31):7804–7810CrossRefPubMedGoogle Scholar
  16. 16.
    Heemskerk-Gerritsen BA et al (2015) Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 107(5):djv033CrossRefPubMedGoogle Scholar
  17. 17.
    Finch AP et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32(15):1547–1553PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Metcalfe KA et al (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122(9):2017–2022PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Finch A, Evans G, Narod SA (2012) BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Women’s Health 8(5):543–555CrossRefPubMedGoogle Scholar
  20. 20.
    Kotsopoulos J et al (2014) Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 143(3):579–586CrossRefPubMedGoogle Scholar
  21. 21.
    Widschwendter M et al (2013) The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol 14(12):1226–1232CrossRefPubMedGoogle Scholar
  22. 22.
    Finch AP et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32(15):1547–1553PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Beral V, Million C (2003) Women Study, Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427CrossRefPubMedGoogle Scholar
  24. 24.
    Pike MC et al (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17–35PubMedGoogle Scholar
  25. 25.
    Horwitz KB et al (2008) Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 105(15):5774–5779PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Horwitz KB, Sartorius CA (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93(9):3295–3298PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Gonzalez-Suarez E et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103–107CrossRefPubMedGoogle Scholar
  28. 28.
    Schramek D et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98–102PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Joshi PA et al (2010) Progesterone induces adult mammary stem cell expansion. Nature 465(7299):803–807CrossRefPubMedGoogle Scholar
  30. 30.
    Joshi PA et al (2015) RANK signaling amplifies WNT-responsive mammary progenitors through R-SPONDIN1. Stem Cell Rep 5(1):31–44CrossRefGoogle Scholar
  31. 31.
    Mavaddat N et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21(1):134–147PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Kotsopoulos J et al (2005) Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 7(5):R833–R843PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Kotsopoulos J et al (2005) Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 16(6):667–674CrossRefPubMedGoogle Scholar
  34. 34.
    Kropp S et al (2007) Good agreement between physician and self-reported hormone therapy data in a case-control study. J Clin Epidemiol 60(12):1280–1287CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Joanne Kotsopoulos
    • 1
  • Tomasz Huzarski
    • 2
  • Jacek Gronwald
    • 2
  • Pal Moller
    • 3
    • 4
  • Henry T. Lynch
    • 5
  • Susan L. Neuhausen
    • 6
  • Leigha Senter
    • 7
  • Rochelle Demsky
    • 8
    • 9
  • William D. Foulkes
    • 10
  • Charis Eng
    • 11
  • Beth Karlan
    • 12
  • Nadine Tung
    • 13
  • Christian F. Singer
    • 14
  • Ping Sun
    • 1
  • Jan Lubinski
    • 2
  • Steven A. Narod
    • 1
    Email author
  1. 1.Women’s College Research InstituteWomen’s College HospitalTorontoCanada
  2. 2.Department of Genetics and Pathology, International Hereditary Cancer CenterPomeranian Medical UniversitySzczecinPoland
  3. 3.Inherited Cancer Research Group, Department for Medical Genetics, The Norwegian Radium HospitalOslo University HospitalOsloNorway
  4. 4.Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium HospitalOslo University HospitalOsloNorway
  5. 5.Department of Preventive Medicine and Public HealthCreighton University School of MedicineOmahaUSA
  6. 6.Department of Population SciencesBeckman Research Institute of City of HopeDuarteUSA
  7. 7.Division of Human GeneticsThe Ohio State University Medical Center, Comprehensive Cancer CenterColumbusUSA
  8. 8.Division of Gynecologic Oncology, Princess Margaret Cancer CentreUniversity Health NetworkTorontoCanada
  9. 9.Department of Molecular GeneticsUniversity of TorontoTorontoCanada
  10. 10.Program in Cancer Genetics, Department of Oncology and Human GeneticsMcGill UniversityMontréalCanada
  11. 11.Genomic Medicine Institute and Center for Personalized Genetic HealthcareCleveland ClinicClevelandUSA
  12. 12.Gynecology OncologyCedars Sinai Medical CenterLos AngelesUSA
  13. 13.Beth Israel Deaconess Medical CenterBostonUSA
  14. 14.Department of Obstetrics and Gynecology and Comprehensive Cancer CenterMedical University of ViennaViennaAustria

Personalised recommendations